ONEMEDNET CORPORATION Revenue, Remaining Performance Obligation, Percentage
ONEMEDNET CORPORATION (ONMD) had Revenue, Remaining Performance Obligation, Percentage of 10.00% as of 2025-12-31, per its S-1/A filed 2026-07-08.
Financial Statements › Notes
us-gaap:RevenueRemainingPerformanceObligationPercentage · last filed 2026-07-08
- 2025-12-31: Revenue, Remaining Performance Obligation, Percentage 10.00%.
- 2024-12-31: Revenue, Remaining Performance Obligation, Percentage 10.00%.
| Period end | Revenue, Remaining Performance Obligation, Percentage |
|---|---|
| 2025-12-31 | 10.00% S-1/A · filed 2026-07-08 |
| 2024-12-31 | 10.00% S-1/A · filed 2026-07-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |